US 11,911,620 B2
Neuromodulation for treatment of brain and eye strokes and/or acute dysregulated reduced cerebral or ocular blood flow
Ismail Mohammed Yousif Musallam, Jerusalem (IL)
Filed by Ismail Mohammed Yousif Musallam, Jerusalem (IL)
Filed on Jul. 19, 2020, as Appl. No. 16/932,773.
Claims priority of provisional application 62/876,791, filed on Jul. 22, 2019.
Prior Publication US 2021/0023372 A1, Jan. 28, 2021
Int. Cl. A61N 1/04 (2006.01); A61K 31/045 (2006.01); A61K 31/375 (2006.01); A61N 1/36 (2006.01); A61N 5/06 (2006.01); A61N 7/00 (2006.01)
CPC A61N 1/36046 (2013.01) [A61K 31/045 (2013.01); A61K 31/375 (2013.01); A61N 1/0456 (2013.01); A61N 1/36025 (2013.01); A61N 5/062 (2013.01); A61N 5/0622 (2013.01); A61N 7/00 (2013.01); A61N 2007/0026 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for prompt treatment of acute ischemic disorders of at least one of the brain and the eye via repeated application of non-invasive ophthalmic nerve stimulation (ONS) in combination with intravenous administration of pharmacological doses of ascorbic acid within 3-24 hours from an onset of the acute ischemic disorder, wherein an effective amount of ONS is administered to a subject in need thereof.